Semaglutide (Ozempic), FDA-approved for type 2 diabetes in 2017, has garnered attention for inducing weight loss through satiety triggers, delaying stomach emptying, and reducing appetite. Our aims to determine the amount of awareness among obese patients in KSA regarding the potential adverse effects of Ozempic. A cross-sectional questionnaire survey was conducted in KSA, involving adult obese individuals. Participants under 18, non-Saudi citizens, and non-obese individuals were excluded. The sample size were determined using the Raosoft calculator, establishing a minimum sample size of 377 at a 95% confidence level with a 5% maximum marginal error. Statistical analysis was performed using SPSS 27. A total of 1449 individuals participated. The data indicates that 73.8% of respondents exhibited "poor awareness," while 21.9% displayed "moderate awareness," and 4.3% showed "high awareness." Notably, the highest percentage of individuals with high awareness scores was in the 21-30 age group (45.9%), whereas individuals older than 60 had the lowest percentage (3.9%), revealing a significant association with age (p-value=0.017). Gender also played a significant role in awareness scores, with females having a notably higher percentage of individuals with high awareness (71.7%) compared to males (28.3%) (P-value=0.010). The study revealed extremely low levels of awareness among participants. Age and gender demonstrated significant associations with awareness scores. This highlights a critical need for targeted interventions in healthcare. Improving health outcomes for obese patients in KSA necessitates healthcare practitioners' focused efforts on enhancing patient education, mitigating cultural and language barriers, and fostering collaborative decision-making processes.